Literature DB >> 7945407

Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte.

G Wagner1, G Schuch, T P Akerboom, H Sies.   

Abstract

In vivo transport in plasma and in vitro transfer of ebselen to binding sites in the hepatocyte were studied. More than 90% of intravenously administered ebselen in mouse plasma is bound by selenium-sulfur bonds to reactive thiols in serum albumin. In in vitro experiments the uptake of [14C]-ebselen from a complex prepared with bovine serum albumin (BSA) was determined in isolated perfused rat liver. Radioactive ebselen metabolites were excreted into bile. In isolated hepatocytes, radioactivity was bound to all subcellular organelles. Ebselen is transferred from the BSA complex to membrane-associated proteins after reductive cleavage of the Se-S bond effected by endogenous protein thiols. In contrast, when proteins were separated by dialysis membranes, ebselen transfer from its BSA complex occurred only in the presence of externally added reductants. Among the physiological reductants tested, ebselen release from the BSA complex was highest with glutathione (75%) and lowest with ascorbic acid (less than 10%). Quantitative release of ebselen from its BSA complex was only achieved by the combined action of reductant, notably 2-mercaptoethanol, and guanidine thiocyanate, suggesting that ebselen interacts with proteins by covalent Se-S bonds as well as by ionic charge interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945407     DOI: 10.1016/0006-2952(94)90150-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.

Authors:  Gajendra Kumar Azad; Raghuvir S Tomar
Journal:  Mol Biol Rep       Date:  2014-08       Impact factor: 2.316

2.  Screening for dimethylarginine dimethylaminohydrolase inhibitors reveals ebselen as a bioavailable inactivator.

Authors:  Thomas Linsky; Yun Wang; Walter Fast
Journal:  ACS Med Chem Lett       Date:  2011       Impact factor: 4.345

3.  Ebselen induced C6 glioma cell death in oxygen and glucose deprivation.

Authors:  Honglian Shi; Shimin Liu; Minoru Miyake; Ke Jian Liu
Journal:  Chem Res Toxicol       Date:  2006-05       Impact factor: 3.739

4.  Human blood cells support the reduction of low-density-lipoprotein-associated cholesteryl ester hydroperoxides by albumin-bound ebselen.

Authors:  J Christison; H Sies; R Stocker
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

5.  High-throughput screening using the differential radial capillary action of ligand assay identifies ebselen as an inhibitor of diguanylate cyclases.

Authors:  Ori J Lieberman; Mona W Orr; Yan Wang; Vincent T Lee
Journal:  ACS Chem Biol       Date:  2013-11-04       Impact factor: 5.100

6.  In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.

Authors:  Pablo Andrei Nogara; Folorunsho Bright Omage; Gustavo Roni Bolzan; Cássia Pereira Delgado; Michael Aschner; Laura Orian; João Batista Teixeira Rocha
Journal:  Mol Inform       Date:  2021-05-21       Impact factor: 4.050

7.  A safe lithium mimetic for bipolar disorder.

Authors:  Nisha Singh; Amy C Halliday; Justyn M Thomas; Olga V Kuznetsova; Rhiannon Baldwin; Esther C Y Woon; Parvinder K Aley; Ivi Antoniadou; Trevor Sharp; Sridhar R Vasudevan; Grant C Churchill
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines.

Authors:  Paul D Hanavan; Chad R Borges; Benjamin A Katchman; Douglas O Faigel; Thai H Ho; Chen-Ting Ma; Eduard A Sergienko; Nathalie Meurice; Joachim L Petit; Douglas F Lake
Journal:  Oncotarget       Date:  2015-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.